Commercial Novartis shares fall as Entresto sales weaken PharmaphorumNovartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.CardiovascularRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Seaport and Hemab target $180m IPOs as biotech listings accumulateNext: Merck KGaA and Remepy join forces to develop combo drug-digital therapies Related Stories Commercial Moderna builds commercial muscle as new launches loom pharminent June 17, 2026 Commercial ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option pharminent June 8, 2026 Commercial Lilly and Novo face off at ADA 2026 as others seek to compete in obesity pharminent June 5, 2026
